Find Paper, Faster
Example:10.1021/acsami.1c06204 or Chem. Rev., 2007, 107, 2411-2502
Current perspectives of the use of Sodium Glucose Transport-2 Inhibitors for patients with heart failure and chronic kidney disease.
Journal of Cardiovascular Pharmacology  (IF3.105),  Pub Date : 2021-11-03, DOI: 10.1097/fjc.0000000000001176
Etty Vider, Ravit Sapir, Eli Mosseri, Elizabeth Gavioli

Sodium-glucose co-transporter-2 inhibitors (SGLT-2 inhibitors) are a relatively new class of drugs approved for the treatment of type 2 diabetes (T2DM). In 2021, the American College of Cardiology recommended the use of SGLT-2 inhibitors in patients with heart failure, with or without T2D, due to their morbidity and mortality benefits. The review provides an overview of the efficacy and safety of SGLT-2 inhibitors in heart failure and chronic kidney disease. We review the existing literature for SGLT-2 inhibitors by searching Pubmed.gov using the keywords of SGLT-2 inhibitors, heart failure and chronic kidney disease. A clinical treatment pathway is provided to help guide clinicians in choosing an SGLT-2 inhibitor for their patients with chronic heart failure and chronic kidney disease.